GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of ...

UK-based GlaxoSmithKline PLC (GB:GSK) hits a key milestone in its ovarian cancer trial, testing Zejula (niraparib) and Jemperli (dostarlimab). The company announced that its FIRST-ENGOT-OV44 phase ...

GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS ...

(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. The First-Engot-OV44 phase III trial evaluated ...

GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS ...

The trial, sponsored by GSK and led by the French cooperative group GINECO, involved patients with stage III or IV nonmucinous epithelial ovarian cancer. Participants were initially assigned to ...

GSK), a prominent pharmaceutical company with a market capitalization of $67.35 billion and currently trading near its 52-week low, today disclosed positive outcomes from its phase III FIRST trial, ...